Shares of Biogen Inc. rallied 3.07% to $129.44 Monday, on what proved to be an all-around great trading session for the stock ...

Cambridge, Massachusetts-based Biogen Inc. (BIIB) discovers, develops, manufactures, and delivers therapies for treating ...

Analysts at BMO Capital Markets said in a weekend note that a non-invasive blood test could help boost uptake of Alzheimer’s ...

The U.S. Food and Drug Administration has cleared Fujirebio Diagnostics' blood test to diagnose Alzheimer's disease, the ...

This was the stock's second consecutive day of losses.

Biogen will open a West Coast hub in South San Francisco after acquiring a Peninsula drugmaker. HI-Bio's operations have ...

EMA’s reluctance in approving drugs for the condition underscores Europe’s prioritisation of long-term safety over rapid access.

Biogen says it is the first drugmaker in the US to get FDA approval for a biosimilar of Roche’s $3 billion blockbuster product Actemra. The intravenous biosimilar of IL-6 inhibitor Actemra ...

Sales of multiple sclerosis drugs such as Tecfidera fell 11% to $953 million. Sales of rare disease drugs, including Skyclarys and Spinraza, rose 33% to $563 million in the quarter. Revenue rose 6% to ...

Searching For Answers C-Suite Leaders Awards The San Francisco Business Times is now seeking nominations for our annual C-Suite Leaders Awards, which highlights leading local executives and their ...

Biogen Inc.'s earnings and share price have declined due to falling Multiple Sclerosis treatment revenue; new drugs and pipeline show promise but haven't offset losses yet. Biogen's Multiple ...

Stay updated with the latest stock market news and live updates. Get real-time insights on Sensex Today, Nifty Live, stock market today, IPO news and more on Business Standard.